• Enerdrape

  Led · Debt Financing · Feb 2026

  Enerdrape is a Western Switzerland cleantech startup that manufactures modular geothermal panels designed for installation in underground settings such as parking garages, tunnels and basements. The panels capture both shallow geothermal energy and residual heat, which is then transferred to a building’s heating or cooling system via a heat pump. According to the company, every square meter of Enerdrape panels can deliver enough thermal energy for up to 23 square meters of living space, underscoring a strong efficiency metric. The solution eliminates the need for drilling, lowering installation complexity and cost relative to traditional geothermal systems. The company plans to use newly secured funding to expand its team, accelerate market development efforts and build new digital tools to support deployment. Enerdrape’s business model focuses on retrofitting existing underground infrastructure, unlocking an untapped renewable energy source for urban areas. Its recent financing indicates growing traction and provides additional runway for commercialization.

• Ex Nunc Intelligence

  Led · Debt Financing · Jun 2024

  Founded in 2022 and headquartered in Lausanne, Switzerland, Ex Nunc Intelligence has built Silex, an AI legal-intelligence platform that interprets natural-language legal queries and returns documented answers grounded in authoritative legal sources. The company has created a proprietary legal intelligence stack that covers data ingestion, legal structuring, retrieval, reasoning, and generation, including its own AI models. Silex is already used by hundreds of law firms, notary offices, and corporate legal departments, demonstrating early market traction in the B2B legal sector. The product roadmap includes rolling out specialized AI agents tailored to individual legal domains and expanding the underlying legal knowledge infrastructure. Recent funding will accelerate these development efforts and support broader market rollout. Although still at the pre-revenue or undisclosed-revenue stage, the company’s adoption figures suggest growing demand for automated legal research solutions.

• Hemostod

  Led · Debt Financing · Jun 2024

  HemostOD is a pre-clinical healthcare company based in Lausanne, Switzerland that manufactures universal human blood platelets entirely ex vivo using immortalized hematopoietic stem cells and proprietary bioreactor technology. By eliminating the need for human donors, the company aims to solve chronic platelet shortages that hinder treatments ranging from cancer care to trauma response. Its platform is designed to offer safer, readily available, and scalable platelet supplies while also enabling future applications in hematology and advanced therapeutic delivery. The firm is currently transitioning from proof-of-concept research to industrialization. With the latest capital infusion, HemostOD will build a commercial-scale pilot production line and prepare for a pre-IND meeting with the U.S. FDA. These steps are intended to validate manufacturing scalability and align the product with regulatory expectations. The CHF 4.3 million seed-extension financing strengthens the company’s balance sheet as it advances toward clinical development and eventual commercialization.

• Voltiris

  Led · Debt Financing · Apr 2024

  Voltiris develops colour-optimized photovoltaic modules that convert greenhouses into renewable powerplants by filtering light so plants receive needed wavelengths while other components are reflected onto photovoltaics. Its spectral filtering technology reduces greenhouses' dependence on gas and the electricity grid and cuts CO2 emissions without reducing crop yields. The company has already installed roughly 400 modules across 12 projects in five countries. Voltiris plans to use a CHF 500,000 Tech Growth loan from the Foundation for Technological Innovation (FIT) to further industrialize its solution and execute a commercialisation plan with flagship projects in Switzerland and the Netherlands. If installed across all Swiss greenhouses the technology could save CO2 emissions equivalent to 18,000 households. The FIT loan is intended to accelerate industrialization and the rollout of commercial installations. Voltiris develops the first solar modules designed to be installed inside existing greenhouses; their spectral-filtering panels direct essential light to crops while converting unused light into renewable energy. The modules maintain crop yields, support behind-the-meter consumption, integrate with existing greenhouse infrastructure, and require no special permits. The company received an initial 12 months of Biopôle Start-up funding, which provides visibility, recognition, financial backing, coaching, and supplementary services. Voltiris will allocate a significant portion of the funds to procure advanced tools to further its expertise in plant photobiology. The startup is scaling a pipeline of projects in Switzerland, the Netherlands, and France and is preparing a CHF 3 million seed round to power up commercial activities. Voltiris builds solar modules that allow a double use of greenhouse land by producing electricity while maintaining crop yields beneath the panels. Its modules do not require installation permits, which accelerates deployment and adoption. The start-up raised CHF 1.4M in a Pre-Seed round to accelerate development and commercialisation, expand commercial pilots, prepare for industrial production, and add key team competencies. In early 2023 Voltiris will commence multiple solar projects with tomato and flower growers in Switzerland and the Netherlands. It will also run a one-year agronomical tomato study with Wageningen University at its Bleiswijk testing facilities. These projects are intended to scale through 2023 and lead to full-scale commercialization in 2024. Voltiris has developed colour-optimized, greenhouse-compatible photovoltaic modules and a self-developed sun-tracking system that let through the red and blue light plants need while reflecting green and near-infrared to photovoltaic cells to generate electricity. The company says this approach produces renewable energy without impacting agricultural yield and delivers a competitive cost of energy and strong ROI for growers. A three-person team supported by a broad advisory network is conducting live pilots in collaboration with HES‑SO and Agroscope. Voltiris has submitted two patents covering high photovoltaic yield and solar tracking. The company received CHF180,000 of support from Innosuisse, HES‑SO and Agroscope for an agronomical study and a CHF100,000 Tech Seed loan from the Foundation for Technological Innovation (FIT) to fund ongoing pilots. Using the FIT loan, Voltiris plans to prepare industrialization, execute larger-scale pilot projects and complete technical development to unlock customer access, then begin commercialization with selected partners in Switzerland and the Netherlands before expanding globally.

• ARTIRIA Medical

  Participated · Debt Financing · Feb 2024

  Artiria Medical builds a real-time deflectable guidewire technology intended for neurointerventional procedures to improve minimally invasive treatment of stroke. The company reports promising first-in-human results and has obtained FDA clearance. Its technology is already showing traction among neurointerventional physicians. Artiria secured financing to enable further clinical deployment and to complete its clinical studies. The recent financing mix underscores investor support as the company advances clinical work. Artiria Medical, an EPFL spin-off, has developed a neurovascular guiding system designed to navigate tiny brain arteries and speed delivery of life‑saving stroke therapies. The company says its technology integrates well into current clinical practice and addresses delays caused by challenging device navigation. With the new funding, Artiria plans to significantly advance the clinical and regulatory deployment of its first product. The announcement notes the company won Venture Kick and participated in Venture Leaders Life Science, which helped prepare fundraising and investor outreach. No revenue or user metrics were disclosed in the article. The financing is intended to accelerate clinical development and regulatory progress toward patient use. ARTIRIA Medical, an EPFL spin-off founded in August 2019 by Guillaume Petit‑Pierre and Marc Boers, has developed a patented micro‑actuated guidewire that facilitates micromotion deep in brain arteries to enable seamless navigation to cerebral lesions. The device aims to ease minimally invasive stroke procedures, reduce treatment duration, and improve patient outcomes against the backdrop of some 13 million annual strokes. The company plans to use its new funding to accelerate clinical validation and pursue regulatory approval of its first product. Less than one year after its foundation the start‑up closed a CHF 3 million financing to support those next stages. Leadership includes the two founders, and the company recently appointed Jacques Essinger, Jean‑Pierre Rosat, and Didier Cowling to its board to add medical device expertise.

No current team members are available.